Whole-Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia

被引：0

作者：

Ravindra, N. ^{[1
]}

Hourigan, C. ^{[1
]}

Dillon, L. ^{[2
]}

Lack, J. ^{[3
]}

Dalgard, C. ^{[4
]}

vanCollenburg, E. ^{[5
]}

Corner, A. ^{[5
]}

Beppu, L. ^{[6
]}

Erba, H. ^{[7
]}

Othus, M. ^{[8
]}

Radich, J. ^{[6
,9
]}

机构：

[1] NIH, Bldg 10, Bethesda, MD 20892 USA

[2] NHLBI, Lab Myeloid Malignancies, Bldg 10, Bethesda, MD 20892 USA

[3] NIH, Integrated Data Sci Sect, Bldg 10, Bethesda, MD 20892 USA

[4] Uniformed Serv Univ Hlth Sci, Amer Genome Ctr, Bethesda, MD 20814 USA

[5] Digital Biol Grp, Biorad Labs, Pleasanton, CA USA

[6] Fred Hutchinson Canc Ctr, Translat Sci & Therapeut Div, Seattle, WA USA

[7] Duke Univ, Sch Med, Durham, NC USA

[8] Fred Hutchinson Canc Ctr, Publ Hlth Sci Div, Seattle, WA USA

[9] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA

来源：

JOURNAL OF MOLECULAR DIAGNOSTICS | 2023年 / 25卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

H020

引用

页码：S36 / S36

页数：1

共 50 条

[21] Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
Hasserjian, Robert P.
Steensma, David P.
Graubert, Timothy A.
Ebert, Benjamin L.
BLOOD, 2020, 135 (20) : 1729 - 1738
[22] Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
Marisa J. L. Aitken
Farhad Ravandi
Keyur P. Patel
Nicholas J. Short
Journal of Hematology & Oncology, 14
[23] Whole-genome sequencing of 988 myeloid neoplasms
Okazaki, Koji
Takamori, Hiroyuki
Fukushima, Hidehito
Yokoyama, Kazuaki
Mimura, Kaito
Motomura, Masanori
Okuda, Rurika
Saiki, Ryunosuke
Ogasawara, Tatsuki
Nakagawa, Masahiro M.
Yoshida, Kenichi
Ochi, Yotaro
Katayama, Kotoe
Imoto, Seiya
Ogawa, Seishi
Nannya, Yasuhito
CANCER SCIENCE, 2025, 116 : 1 - 1
[24] Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
Cluzeau, Thomas
Lemoli, Roberto M.
McCloskey, James
Cooper, Todd
CANCERS, 2022, 14 (05)
[25] The present and future of measurable residual disease testing in acute myeloid leukemia
Blachly, James S.
Walter, Roland B.
Hourigan, Christopher S.
HAEMATOLOGICA, 2022, 107 (12) : 2810 - 2822
[26] Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
Aitken, Marisa J. L.
Ravandi, Farhad
Patel, Keyur P.
Short, Nicholas J.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[27] Widespread use of measurable residual disease in acute myeloid leukemia practice
Epstein-Peterson, Zachary D.
Devlin, Sean M.
Stein, Eytan M.
Estey, Elihu
Tallman, Martin S.
LEUKEMIA RESEARCH, 2018, 67 : 92 - 98
[28] Delving the depths of measurable residual disease negativity in acute myeloid leukemia
Freeman, Sylvie D.
HAEMATOLOGICA, 2022, 107 (12) : 2776 - 2778
[29] The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia
Buccisano, Francesco
Hourigan, Christopher S.
Walter, Roland B.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (06) : 547 - 556
[30] The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia
Francesco Buccisano
Christopher S. Hourigan
Roland B. Walter
Current Hematologic Malignancy Reports, 2017, 12 : 547 - 556

← 1 2 3 4 5 →